Premenstrual SyndromeNCT07655466
Effects of Seed Cycling Capsules on Premenstrual Syndrome Symptoms and Menstrual Cycle Length
A study testing Two Moons Seed Cycling Capsules in people with Premenstrual Syndrome and Menstrual Symptoms, run by Superlune Inc. d/b/a Two Moons Health at 1 site in United States.
Trial summary
This virtual, single-arm clinical trial will evaluate the effects of Seed Cycling Capsules on symptoms associated with premenstrual syndrome (PMS) and menstrual cycle characteristics. Forty female participants aged 18 to 45 years will use the study products daily for two menstrual cycles. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Premenstrual Syndrome, Menstrual Symptoms
- What is being tested?
- Two Moons Seed Cycling Capsules
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Jul 2025to 27 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be female.
- Be 18-45 years of age.
- Have experienced at least five of the following symptoms during the last three menstrual cycles:
- Heavy flow Prolonged, shortened, or irregular periods Headaches or migraines Low mood Fatigue Bloating Premenstrual or menstrual cramps Breast tenderness Poor sleep Constipation or diarrhea Weight gain or fluctuations Irritability or anger Sick days or reduced social activity due to menstrual symptoms Hormonal acne
- Be generally healthy.
- Have a menstrual cycle length between 23 and 35 days.
- Track menstrual cycles and be able to predict period dates.
- Be willing to refrain from taking products, medications, or supplements targeting menstrual health during the study.
Who cannot join
- Use of hormonal contraception.
- Allergy to sesame.
- Chronic conditions that would interfere with study participation, including oncological and psychiatric disorders.
- Pregnant, breastfeeding, or trying to conceive.
- Unwillingness to follow the protocol.
- Menopause or menopausal symptoms.
Show all 13Show fewer
- Recent or planned invasive medical procedures.
- History of substance abuse.
- Diabetes or other endocrine-related conditions.
- Current or planned participation in another research study.
- Use of hormone-modulating medications or therapies.
- Planned insertion or replacement of an IUD within 12 weeks.
- Diagnosis of endometriosis, polycystic ovary syndrome (PCOS), or adenomyosis.
Trial locations and contacts
1 site in 1 country.
About this study
This virtual, single-arm clinical trial will evaluate the effects of Seed Cycling Capsules on symptoms associated with premenstrual syndrome (PMS) and menstrual cycle characteristics. Forty female participants aged 18 to 45 years will use the study products daily for two menstrual cycles. Participants will complete questionnaires at baseline, at the end of their period during Cycle 1, and at the end of their period during Cycle 2.
- Conditions
- Premenstrual Syndrome, Menstrual Symptoms
- Being tested
- Two Moons Seed Cycling Capsules
- Keywords
- Hormonal Imbalance, Menstrual Health
- Medical subject headings
- Premenstrual Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Two Moons Seed Cycling CapsulesDietary supplement
Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. Participants will take two capsules with the first meal of the day according to the following schedule: Zest Capsules from Days 1-14 of the cycle, and Zen Capsules from Days 15-28 of the cycle. Participants will continue this schedule for two menstrual cycles regardless of when subsequent menstrual periods occur.
| Study group | Role | What they receive |
|---|---|---|
| Seed Cycling Capsules | Experimental | Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. Receives: Dietary Supplement: Two Moons Seed Cycling Capsules |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Menstrual Cramp Severity
Self-reported severity of premenstrual and menstrual cramps assessed using study questionnaires and compared between Baseline, Cycle 1, and Cycle 2.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Bloating Severity
Self-reported severity of abdominal bloating associated with the menstrual cycle assessed using study questionnaires.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Fatigue Severity
Self-reported fatigue associated with the menstrual cycle assessed using study questionnaires.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Hormonal Acne Severity
Self-reported severity and frequency of hormonal acne symptoms assessed using study questionnaires.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Mood Symptoms
Self-reported mood-related symptoms including low mood, irritability, and anger associated with the menstrual cycle.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Sleep Quality
Self-reported sleep quality and insomnia symptoms associated with the menstrual cycle.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Breast Tenderness Severity
Self-reported breast tenderness associated with the menstrual cycle.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Change in Libido
Self-reported sex drive and libido associated with the menstrual cycle.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Secondary outcomes (3)
Participant Assessment of Overall Menstrual Experience
Participant-reported assessment of the overall effect of the study product on menstrual health and menstrual cycle experience.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Participant Satisfaction With Seed Cycling Capsules
Participant-reported satisfaction with the study product following use during the study period.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Participant Perception of Product Effectiveness
Participant-reported perception of the effectiveness of the study product in improving menstrual symptoms.
Measured: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start8 Jul 2025
- Primary completion27 Sep 2025
- Study completion27 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Premenstrual SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superlune Inc. d/b/a Two Moons Health
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07655466
- Sponsor's protocol ID
- #20756
- Status last verified
- Jun 2026
- First submitted
- 9 Jun 2026
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Seed Cycling Capsules on Premenstrual Syndrome Symptoms and Menstrual Cycle Length
- ClinicalTrials.gov ID
- NCT07655466
- Acronym / sponsor ID
- #20756
- Conditions
- Premenstrual Syndrome, Menstrual Symptoms
- Keywords
- Hormonal Imbalance, Menstrual Health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Superlune Inc. d/b/a Two Moons HealthIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 8 Jul 2025 (actual)
- Primary completion
- 27 Sep 2025 (actual)
- Study completion
- 27 Sep 2025 (actual)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This virtual, single-arm clinical trial will evaluate the effects of Seed Cycling Capsules on symptoms associated with premenstrual syndrome (PMS) and menstrual cycle characteristics. Forty female participants aged 18 to 45 years will use the study products daily for two menstrual cycles. Participants will complete questionnaires at baseline, at the end of their period during Cycle 1, and at the end of their period during Cycle 2.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Seed Cycling Capsules | Experimental | Dietary Supplement: Two Moons Seed Cycling CapsulesParticipants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Be female.
- Be 18-45 years of age.
- Have experienced at least five of the following symptoms during the last three menstrual cycles:
- Heavy flow Prolonged, shortened, or irregular periods Headaches or migraines Low mood Fatigue Bloating Premenstrual or menstrual cramps Breast tenderness Poor sleep Constipation or diarrhea Weight gain or fluctuations Irritability or anger Sick days or reduced social activity due to menstrual symptoms Hormonal acne
- Be generally healthy.
Key exclusion criteria (13 listed)
- Use of hormonal contraception.
- Allergy to sesame.
- Chronic conditions that would interfere with study participation, including oncological and psychiatric disorders.
- Pregnant, breastfeeding, or trying to conceive.
- Unwillingness to follow the protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Two Moons Seed Cycling CapsulesParticipants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. Participants will take two capsules with the first meal of the day according to the following schedule: Zest Capsules from Days 1-14 of the cycle, and Zen Capsules from Days 15-28 of the cycle. Participants will continue this schedule for two menstrual cycles regardless of when subsequent menstrual periods occur. | Dietary supplement | Seed Cycling Capsules |
Primary outcome
Change in Menstrual Cramp Severity
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported severity of premenstrual and menstrual cramps assessed using study questionnaires and compared between Baseline, Cycle 1, and Cycle 2.
Change in Bloating Severity
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported severity of abdominal bloating associated with the menstrual cycle assessed using study questionnaires.
Change in Fatigue Severity
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported fatigue associated with the menstrual cycle assessed using study questionnaires.
Change in Hormonal Acne Severity
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported severity and frequency of hormonal acne symptoms assessed using study questionnaires.
Change in Mood Symptoms
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported mood-related symptoms including low mood, irritability, and anger associated with the menstrual cycle.
Change in Sleep Quality
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported sleep quality and insomnia symptoms associated with the menstrual cycle.
Change in Breast Tenderness Severity
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported breast tenderness associated with the menstrual cycle.
Change in Libido
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Self-reported sex drive and libido associated with the menstrual cycle.
3 secondary outcomes
Participant Assessment of Overall Menstrual Experience
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Participant Satisfaction With Seed Cycling Capsules
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Participant Perception of Product Effectiveness
Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
Related trials for Premenstrual Syndrome
Not yet recruitingPhase 1
MLS101 Study in PMDD
Premenstrual Dysphoric Disorder ( PMDD), PMDD
Not yet recruiting
Integrated Core Stability Exercises and Yoga Program on Premenstrual Syndrome
Premenstrual Syndrome
Enrolling by invitation
Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause
Perimenopause, PMDD
Recruiting
A Clinical Trial to Evaluate the Effects of the Kaia Relief - Cycle System on Premenstrual Symptom Severity, Menstrual Discomfort, and Overall Well-Being in Premenopausal Women.
Premenstrual Syndrome, Menstrual Discomfort
RecruitingObservational study
Occupational Physicians Facing Premenstrual Dysphoric Disorder: Knowledge, Perceptions and Practices in Occupational Health
Premenstrual Dysphoric Disorder (PMDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Two Moons Seed Cycling Capsules in people with Premenstrual Syndrome and Menstrual Symptoms, run by Superlune Inc. d/b/a Two Moons Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Menstrual Cramp Severity (time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.